MedTrace Logo

The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.

NCT05033158 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2023-06-15

No results posted yet for this study

Summary

This study investigates the immune response in the cancer population in Belgium being vaccinated with an approved vaccine types being authorized for use in Belgium. This question needs to be answered to make sure that this vulnerable population is properly protected against possible SARS-CoV-2 infection and that vaccine administration is safe.

Conditions

Interventions

OTHER

Blood sampling

Blood sampling before and after COVID-19 vaccination

Sponsors & Collaborators

  • KomOpTegenKanker (non-profit organization)

    collaborator UNKNOWN

  • University Hospital, Antwerp

    lead OTHER

Principal Investigators

  • Marc Peeters, Prof. MD · University Hospital, Antwerp

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-31
Completion
2023-06-13

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05033158 on ClinicalTrials.gov